X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs NOVARTIS - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD NOVARTIS WYETH LTD/
NOVARTIS
 
P/E (TTM) x 27.7 328.0 8.5% View Chart
P/BV x 5.3 36.4 14.7% View Chart
Dividend Yield % 1.3 1.3 101.3%  

Financials

 WYETH LTD   NOVARTIS
EQUITY SHARE DATA
    WYETH LTD
Mar-13
NOVARTIS
Mar-18
WYETH LTD/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,044758 137.8%   
Low Rs818579 141.3%   
Sales per share (Unadj.) Rs298.6228.4 130.7%  
Earnings per share (Unadj.) Rs57.231.7 180.4%  
Cash flow per share (Unadj.) Rs58.432.8 178.3%  
Dividends per share (Unadj.) Rs17.0010.00 170.0%  
Dividend yield (eoy) %1.81.5 122.0%  
Book value per share (Unadj.) Rs249.5297.1 84.0%  
Shares outstanding (eoy) m22.7224.69 92.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.12.9 106.6%   
Avg P/E ratio x16.321.1 77.2%  
P/CF ratio (eoy) x15.920.4 78.1%  
Price / Book Value ratio x3.72.2 165.9%  
Dividend payout %29.731.5 94.3%   
Avg Mkt Cap Rs m21,15716,505 128.2%   
No. of employees `0000.50.7 73.7%   
Total wages/salary Rs m4001,445 27.7%   
Avg. sales/employee Rs Th13,787.48,441.3 163.3%   
Avg. wages/employee Rs Th813.02,163.6 37.6%   
Avg. net profit/employee Rs Th2,643.31,173.1 225.3%   
INCOME DATA
Net Sales Rs m6,7835,639 120.3%  
Other income Rs m3531,718 20.5%   
Total revenues Rs m7,1367,357 97.0%   
Gross profit Rs m1,617-63 -2,587.7%  
Depreciation Rs m2725 105.1%   
Interest Rs m655 9.9%   
Profit before tax Rs m1,9381,575 123.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m632792 79.9%   
Profit after tax Rs m1,301784 166.0%  
Gross profit margin %23.8-1.1 -2,151.0%  
Effective tax rate %32.650.3 64.9%   
Net profit margin %19.213.9 138.0%  
BALANCE SHEET DATA
Current assets Rs m6,9849,522 73.3%   
Current liabilities Rs m2,0563,296 62.4%   
Net working cap to sales %72.6110.4 65.8%  
Current ratio x3.42.9 117.6%  
Inventory Days Days9937 271.1%  
Debtors Days Days2428 84.2%  
Net fixed assets Rs m24446 531.1%   
Share capital Rs m227123 184.1%   
"Free" reserves Rs m5,4417,213 75.4%   
Net worth Rs m5,6687,336 77.3%   
Long term debt Rs m250-   
Total assets Rs m7,90111,105 71.1%  
Interest coverage x353.329.5 1,198.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.5 169.1%   
Return on assets %16.57.6 218.8%  
Return on equity %22.910.7 214.8%  
Return on capital %34.022.2 153.2%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1561 25.1%   
Fx outflow Rs m2,6773,630 73.7%   
Net fx Rs m-2,662-3,570 74.6%   
CASH FLOW
From Operations Rs m9231,610 57.3%  
From Investments Rs m317687 46.1%  
From Financial Activity Rs m-481-2,677 18.0%  
Net Cashflow Rs m759-380 -200.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.1 75.0 68.1%  
Indian inst/Mut Fund % 11.3 2.0 565.0%  
FIIs % 7.2 1.6 450.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 21.5 141.4%  
Shareholders   21,978 41,647 52.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  ELDER PHARMA  

Compare WYETH LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, NOVARTIS has posted a net profit of Rs 265 m (up 809.6% YoY). Sales on the other hand came in at Rs 1 bn (down 13.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WYETH LTD WITH

MARKET STATS